Funko Inc vs Nuwellis Inc — how do they compare? Funko Inc trades at $5.74 (market cap $315.21M), while Nuwellis Inc trades at $2.97 (market cap $1.10M). The key difference: Funko Inc is far larger — about 286.6× Nuwellis Inc's market cap, and Funko Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| FNKO | NUWE | |
|---|---|---|
Market Cap | $315.21M | $1.10M |
Sector | Consumer Staples | Technology |
52-Week High | $5.88 | $558.26 |
52-Week Low | $2.46 | $2.80 |
Enterprise Value | $560.25M | -$709.83K |
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $5.55, down 2.46% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/S ratio of 0.34 and strong gross margins near 40%, but negative net income and ROE. Recent quarters have seen earnings beats against expectations, and analyst sentiment leans positive with a 42.86% buy rating and no sell recommendations. News highlights new product launches and a strong Q1 2026 report.
The outlook balances product-driven revenue potential against persistent profitability challenges. Investment opportunity lies in the low valuation multiple and recent earnings momentum, but risks include sustained negative margins, high debt levels, and volatile cash flows from operations.
Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.
The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.
Trailing returns across standard periods
Latest headlines on both assets
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →